Mumbai, Baltimore: Pharma major Lupin announced the launch of its Clobetasol Propionate Spray 0.05% having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Clobetasol Propionate Spray 0.05% is the generic equivalent of Galderma Laboratories, L.P.’s Clobex® Spray, 0.05%. It is indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older..

Clobetasol Propionate Spray 0.05% had annual sales of approximately USD 30.5 million in the US (IQVIA MAT January 2018).

Lupin is the 11^th and 7^th largest generics pharmaceutical company by market capitalization (December 31^st, 2017, Bloomberg) and revenues (September 30^th, 2017, Bloomberg LTM) respectively. The Company is the 4^th largest pharmaceutical player in the US by prescriptions (IQVIA MAT December 2017); 2^nd largest Indian pharmaceutical company by global revenues (September 30^th, 2017, Bloomberg LTM); 6^th largest generic pharmaceutical player in Japan and 5^th largest company in Indian Pharmaceutical Market (IQVIA MAT December 2017).

For the financial year ended 31^st March, 2017, Lupin’s consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3^rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

Or

Arvind Bothra
Head – Investor Relations
Email: arvindbothra@lupin.com
Ph: +91-22-66402137

*Safe Harbor Statement

Clobex® is a registered trademark of Nestle Skin Health S.A.